NEW YORK (GenomeWeb News) – Australian molecular diagnostics firm Genetic Technologies today announced plans to raise about US$9.6 million.

The fund raising will take place in three tranches and net proceeds will be used to expand US distribution of GTG's BrevaGen breast cancer test, and to complete additional studies to add new ethnic groups — Hispanic- and African-Americans — in order to expand the test's addressable market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.